Literature DB >> 20962255

Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria.

Linda Reiling1, Jack S Richards, Freya J I Fowkes, Alyssa E Barry, Tony Triglia, Watcharee Chokejindachai, Pascal Michon, Livingstone Tavul, Peter M Siba, Alan F Cowman, Ivo Mueller, James G Beeson.   

Abstract

Abs targeting blood-stage Ags of Plasmodium falciparum are important in acquired immunity to malaria, but major targets remain unclear. The P. falciparum reticulocyte-binding homologs (PfRh) are key ligands used by merozoites during invasion of erythrocytes. PfRh2a and PfRh2b are functionally important members of this family and may be targets of protective immunity, but their potential role in human immunity has not been examined. We expressed eight recombinant proteins covering the entire PfRh2 common region, as well as PfRh2a- and PfRh2b-specific regions. Abs were measured among a cohort of 206 Papua New Guinean children who were followed prospectively for 6 mo for reinfection and malaria. At baseline, Abs were associated with increasing age and active infection. High levels of IgG to all PfRh2 protein constructs were strongly associated with protection from symptomatic malaria and high-density parasitemia. The predominant IgG subclasses were IgG1 and IgG3, with little IgG2 and IgG4 detected. To further understand the significance of PfRh2 as an immune target, we analyzed PfRh2 sequences and found that polymorphisms are concentrated in an N-terminal region of the protein and seem to be under diversifying selection, suggesting immune pressure. Cluster analysis arranged the sequences into two main groups, suggesting that many of the haplotypes identified may be antigenically similar. These findings provide evidence suggesting that PfRh2 is an important target of protective immunity in humans and that Abs act by controlling blood-stage parasitemia and support its potential for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962255     DOI: 10.4049/jimmunol.1001555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

Review 1.  Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination.

Authors:  Caeul Lim; Selasi Dankwa; Aditya S Paul; Manoj T Duraisingh
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

2.  Patterns of protective associations differ for antibodies to P. falciparum-infected erythrocytes and merozoites in immunity against malaria in children.

Authors:  Jo-Anne Chan; Danielle I Stanisic; Michael F Duffy; Leanne J Robinson; Enmoore Lin; James W Kazura; Christopher L King; Peter M Siba; Freya Ji Fowkes; Ivo Mueller; James G Beeson
Journal:  Eur J Immunol       Date:  2017-09-13       Impact factor: 5.532

3.  Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.

Authors:  Anja Jäschke; Boubacar Coulibaly; Edmond J Remarque; Hermann Bujard; Christian Epp
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

4.  Differences in erythrocyte receptor specificity of different parts of the Plasmodium falciparum reticulocyte binding protein homologue 2a.

Authors:  Karthigayan Gunalan; Xiaohong Gao; Kingsley J L Liew; Peter R Preiser
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans.

Authors:  Saurabh D Patel; Ambroise D Ahouidi; Amy K Bei; Tandakha N Dieye; Souleymane Mboup; Stephen C Harrison; Manoj T Duraisingh
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

6.  Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria.

Authors:  Hodan Ahmed Ismail; Ulf Ribacke; Linda Reiling; Johan Normark; Tom Egwang; Fred Kironde; James G Beeson; Mats Wahlgren; Kristina E M Persson
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

7.  Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.

Authors:  Nicholas T Y Lim; Markus J Harder; Alexander T Kennedy; Clara S Lin; Christopher Weir; Alan F Cowman; Melissa J Call; Christoph Q Schmidt; Wai-Hong Tham
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

8.  Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity.

Authors:  Kristina E M Persson; Freya J I Fowkes; Fiona J McCallum; Nimmo Gicheru; Linda Reiling; Jack S Richards; Danny W Wilson; Sash Lopaticki; Alan F Cowman; Kevin Marsh; James G Beeson
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

9.  Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.

Authors:  Jack S Richards; Thangavelu U Arumugam; Linda Reiling; Julie Healer; Anthony N Hodder; Freya J I Fowkes; Nadia Cross; Christine Langer; Satoru Takeo; Alex D Uboldi; Jennifer K Thompson; Paul R Gilson; Ross L Coppel; Peter M Siba; Christopher L King; Motomi Torii; Chetan E Chitnis; David L Narum; Ivo Mueller; Brendan S Crabb; Alan F Cowman; Takafumi Tsuboi; James G Beeson
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

10.  New antigens for a multicomponent blood-stage malaria vaccine.

Authors:  Faith H Osier; Margaret J Mackinnon; Cécile Crosnier; Gregory Fegan; Gathoni Kamuyu; Madushi Wanaguru; Edna Ogada; Brian McDade; Julian C Rayner; Gavin J Wright; Kevin Marsh
Journal:  Sci Transl Med       Date:  2014-07-30       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.